Meiji and Cerexa drop carbapenem on safety data
This article was originally published in Scrip
Japan's Meiji Seikaand its development partner Cerexa have halted the development of the carbapenem antibiotic ME1036 following a review of safety data from a US Phase I clinical trial.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.